Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis.

Abstract

Etanercept, a tumor necrosis factor (TNF) receptor alpha antagonist is licensed for the treatment in patients affected by polyarticular juvenile idiopathic arthritis, who do not tolerate or had an inadequate response to methotrexate. Infections related to immunosuppression by etanercept are of major concern. We report on a 17-year-old boy with enthesitis-related arthritis who developed a major infection of an urachal cyst 18 months after initiation of etanercept therapy, which required surgery. The urachus had not been symptomatic before.

• Authors: A Holl-Wieden, M Beer, A Marx, R Bonfig, D Tappe, H J Girschick
• Journal: Rheumatology international (Rheumatol Int) Vol. 28 Issue 8 Pg. 819-22 (Jun 2008) ISSN: 0172-8172 [Print] Germany
• PMID: 18193232 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Etanercept

Topics

• Adolescent
• Arthritis, Juvenile (complications, drug therapy)
• Biopsy
• Child
• Etanercept
• Humans
• Immunoglobulin G (therapeutic use)
• Infections (complications)
• Male
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Ultrasonography
• Urachal Cyst (complications, diagnostic imaging, pathology)